ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "outcomes"

  • Abstract Number: 1221 • 2016 ACR/ARHP Annual Meeting

    Environmental Scan of Rheumatoid Arthritis Patient Registries Around the World: An Omeract Initiative

    Natalia V. Zamora1, Maria A. Lopez-Olivo2, Robin Christensen3, Niti Goel4,5, Lars Erik Kristensen6, Vibeke Strand7, Jeffrey R. Curtis8, Beverly Shea9 and Maria Suarez-Almazor10, 1Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 3Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, 4Rheumatology Center of Excellence, Quintiles, Durham, NC, 5Duke University School of Medicine, Durham, NC, 6The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, 7Biopharmaceutical Consultant, Portola Valley, CA, 8Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 9Department of Clinical Epidemiology & Biostatistics, McMaster University, Health Science Centre Hamilton, Ontario, ON, Canada, 10Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX

    Background/Purpose:  Patient registries both disease-and drug-based complement information obtained from clinical trials. Long-term outcomes studies can provide information useful for patients. The Agency for Healthcare…
  • Abstract Number: 1533 • 2016 ACR/ARHP Annual Meeting

    Pregnancy Outcomes in Women with Rheumatoid Arthritis : A Systematic Review and Meta-Analyses

    Anne-Lise Gaillard1, Thomas Barnetche2 and Thierry Schaeverbeke3, 1Rhumatologie, CHU Bordeaux Pellegrin, Bordeaux, France, 2Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, 3Rheumatology Department, Bordeaux Hospital, Bordeaux, France

    Background/Purpose: Actually better control of rheumatoid arthritis (RA) activity leads to new interrogations and daily questions about pregnancy. Only few studies have studied pregnancy outcomes…
  • Abstract Number: 1779 • 2016 ACR/ARHP Annual Meeting

    Remission and Low Lupus Disease Activity Status (LLDAS) Protect Lupus Patients from Damage Occurrence: Data from a Multi-Ethnic, Multinational Latin American Lupus Cohort

    Manuel Ugarte-Gil1,2, Daniel Wojdyla3, Guillermo J. Pons-Estel4, Luis J. Catoggio5, Cristina Drenkard6, Judith Sarano7, Guillermo Berbotto8, Eduardo Borba9, Emilia Sato10, Joao Carlos Brenol11, Oscar Uribe12, Luis Ramirez12, Marlene Guibert-Toledano13, Loreto Massardo14, Mario Cardiel15, Luis H. Silveira16, Rosa Chacón-Díaz17, Graciela S. Alarcón18, Bernado Pons-Estel19 and GLADEL (Grupo LatinoAmericano de Estudio de Lupus), 1Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 2Universidad Cientifica del Sur, Lima, Peru, 3GLADEL consultant, Rosario, Argentina, 4Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, 5Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina, 6Emory University School of Medicine, Atlanta, GA, 7Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, 8Sanatorio Británico, Rosario, Argentina, 9Faculdade de Medicina, Hospital das Clínicas. Universidade de São Paulo, São Paulo, Brazil, 10Rheumatology Division. Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 11Hospital das Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre - RS, Brazil, 12Hospital Universitario “San Vicente de Paul”, Universidad de Antioquia, Medellín, Colombia, 13Rheumatology, Centro de Investigaciones Médico Quirúrgicas, Habana, Ciudad Habana, Cuba, 14Departments of Immunology & Rheumatology, Pontificia Universidad Católica de Chile, Santiago, Chile, 15Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, 16Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, 17Servicio de Reumatología, Hospital Universitario de Caracas, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, 18Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 19Sanatorio Parque, Rosario, Argentina

    Background/Purpose: Recently, definitions of both Remission and LLDAS have been proposed which include disease activity status and medication intake [immunosuppressive (IS) drugs and corticosteroids]. The…
  • Abstract Number: 1955 • 2016 ACR/ARHP Annual Meeting

    Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months

    Benjamin Terrier1, Christian Pagnoux2, Elodie Perrodeau3, Alexandre Karras4, Chahéra Khouatra5, Olivier Aumaître6, Pascal Cohen7, Francois Maurier8, Olivier Decaux9, Hélène Desmurs-Clavel10, Pierre Gobert11, Thomas Quémeneur12, Claire Blanchard-Delaunay13, Pascal Godmer14, Xavier Puéchal15, Luc Mouthon15, Philippe Ravaud16 and Loïc Guillevin15, 1National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 2Mount Sinai Hospital, Toronto, ON, Canada, 3Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 4Nephrology, HEGP, Paris, France, 5CHU Lyon, Lyon, France, 6CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, 7Internal Medicine, Cochin Hospital, Paris, France, 8Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, 9Department of Internal Medicine, Rennes University Hospital, Rennes, France, 10Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, 11Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 12Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, 13Internal Medicine, Centre Hospitalier, Niort, France, 14CH Vannes, Vannes, France, 15Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, 16Hôpital Hôtel Dieu, Paris, France

    Background/Purpose: The previously reported prospective, randomizedÐcontrolled MAINRITSAN trial compared rituximab (RTX) to azathioprine (AZA) for maintenance of ANCA-associated vasculitis (AAV) remissions obtained with a combined…
  • Abstract Number: 2298 • 2016 ACR/ARHP Annual Meeting

    Incident Risk of Acute Gout Among Active Smokers: Data from Nationwide Inpatient Sample

    Dilli Poudel1, Paras Karmacharya1 and Anthony Donato2, 1Internal Medicine, Reading Health System, WEST READING, PA, 2Internal medicine, Reading Health System, WEST READING, PA

    Background/Purpose:  Smoking has been found to be negatively correlated with serum uric acid levels by virtue of reduced production and increased consumption of endogenous anti-oxidant…
  • Abstract Number: 2333 • 2016 ACR/ARHP Annual Meeting

    Comparison of Clinical Outcomes of Total Ankle Arthroplasty Between Biologics and NON-Biologics Treatment Groups in Patients with Rheumatoid Arthritis

    Makoto Hirao1, Kosuke Ebina2, Takaaki Noguchi3, Hideki Tsuboi4, Jun Hashimoto5 and Hideki Yoshikawa6, 1Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, 2Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, 3Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, 4Osaka Rosai Hospital, Sakai, Japan, 5Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, 6Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan

    Background/Purpose:  In progress of medical treatment against rheumatoid arthritis (RA) disease activity using methotrexate (MTX) and/or biologics, we often see cases that require surgical intervention…
  • Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting

    Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis

    Maria Hoehle, Rheumatology, Hamburg, Germany

    Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…
  • Abstract Number: 2603 • 2016 ACR/ARHP Annual Meeting

    Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone

    Ara H. Dikranian1, Rubaiya Mallay2, Mike Marshall3, Megan Francis-Sedlak3 and Robert J. Holt4,5, 1San Diego Arthritis Medical Clinic, San Diego, CA, 2Suncoast Internal Medicine Consultants and Largo Med Center, Largo, FL, 3Horizon Pharma USA, Inc, Lake Forest, IL, 4Medical Affairs, Horizon Pharma, Inc, Lake Forest, IL, 5College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL

    Background/Purpose: Patients with RA have previously demonstrated significant differences in morning stiffness (MS), a debilitating symptom of RA, and other disease measures with delayed release…
  • Abstract Number: 224 • 2016 ACR/ARHP Annual Meeting

    Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study

    Angelo L. Gaffo1, Nicola Dalbeth2, Kenneth G. Saag3, Jasvinder Singh3, Elizabeth J. Rahn1, Amy S. Mudano3, Tuhina Neogi4, Lorenzo Cavagna5, Yi-Hsing Chen6, Ching-Tsai Lin7, Worawit Louthrenoo8, Geraldo Castelar-Pinheiro9, Fernando Perez-Ruiz10, Janitzia Vazquez-Mellado11, Maxim Eliseev12, Lisa K. Stamp13 and William Taylor14, 1Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Auckland, Auckland, New Zealand, 3University of Alabama at Birmingham, Birmingham, AL, 4Boston University School of Medicine, Boston, MA, 5Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 6Taichung Veterans General Hospital, Taichung, Taiwan, 7Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, 8Div of Rheumatology, Dept of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, 9Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, 10Servicio de Reumatología, Vizcaya, Spain, 11Rheumatology, Hospital General de México, Mexico City, Mexico, 12Research Institute of Rheumatology of Russia, Moscow, Russian Federation, 13University of Otago, Christchurch, New Zealand, 14University of Otago, Wellington, New Zealand

    Patient Perception of Gout Flares as a Measure of Outcome: Results from an International Study Background/Purpose: Attacks (flares) are one of the primary manifestations of…
  • Abstract Number: 2804 • 2016 ACR/ARHP Annual Meeting

    Predictors of Survival in Renal Transplantation for Lupus Nephritis – 40 Patients in 40 Years

    Eleana Ntatsaki1, Alba Velo Garcia2, Borja del Carmelo Gracia Tello Sr.3, Alan D. Salama4 and David A. Isenberg5, 1Centre for Rheumatology, University College London, London, United Kingdom, 2Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, 3Internal Medicina, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Zaragoza, Spain, 4Centre for Nephrology, University College London, London, United Kingdom, 5Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE), leading to end stage renal failure…
  • Abstract Number: 320 • 2016 ACR/ARHP Annual Meeting

    The Value of Adjusting for Physical Activity When Measuring Osteoarthritis-Related Pain

    Kelli Allen1, Katherine Hall2, Jennifer H. Lindquist3, Shannon Taylor4 and Cynthia Coffman5, 1University of North Carolina at Chapel Hill and Durham VA Medical Center, Chapel Hill, NC, 2Durham VA Medical Center and Duke University Medical Center, Durham, NC, 3Health Services Research, Durham VA Medical Center, Durham, NC, 4Durham VA Medical Center, Durham, NC, 5Health Services Research, Durham VA Medical Center and Duke University Medical Center, Durham, NC

    Background/Purpose: Measures of chronic pain typically do not account for individuals’ physical activity (PA) levels.  Although PA is essential for managing conditions like osteoarthritis (OA),…
  • Abstract Number: 2829 • 2016 ACR/ARHP Annual Meeting

    Adherence to Treatment and Renal Transplantation Graft Failure in Lupus Nephritis

    Eleana Ntatsaki1, Alba Velo Garcia2, Alan D. Salama3 and David A. Isenberg4, 1Centre for Rheumatology, University College London, London, United Kingdom, 2Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, 3Centre for Nephrology, University College London, London, United Kingdom, 4Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Patient non-adherence has been reported as a potential adverse outcome predictor in renal transplantation (rTp) for patients with lupus nephritis (LN). We investigated potential…
  • Abstract Number: 597 • 2016 ACR/ARHP Annual Meeting

    Comparative Effectiveness of Different Anti-TNF Drugs As First Biological DMARD in RA: Results from the Nationwide Swedish Register 2010-2015

    Thomas Frisell1, Mats Dehlin2, Daniela Di Giuseppe3, Nils Feltelius4, Alf Kastbom5, Carl Turesson6, Johan Askling7 and the ARTIS Study Group, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 3Clinical Epidemiology Unit, Dept. of Medicine, K2, Karolinska institutet, Stockholm, Sweden, 4Swedish Medical Products Agency, Uppsala, Sweden, 5Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, 6Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, 7Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden

    Background/Purpose:  Although evidence from randomized trials suggest similar efficacy and safety on a group level for the different anti-TNF drugs available for the treatment of…
  • Abstract Number: 2950 • 2016 ACR/ARHP Annual Meeting

    Cogan Syndrome: Treatment and Outcome from French Nationwide Retrospective Study and Literature Review of 62 Patients

    CHARLOTTE DURTETTE1, Mathieu Resche Regon2, eric hachulla3, anne Graslands4, Thomas Papo5,6, Jacques Pouchot7, jean Emmanuel kahn8, Thierry Zenone9, cedric landron10, benoit de Wazieres11, Robin Dhote12, Christophe Deligny13, Guillaume Gondran14, Edouard Pertuiset15, thomas quemeneur16, Bertrand Lioger17, Pascal Sève18, Christian Lavigne19, thomas le Galllou20, Mohamed Hamidou21, claire delaunay22, Olivier Fain23 and Arsene Mekinian24, 1SAINT ANTOINE HOSPITAL, PARIS, France, 2biostatistics Saint Louis Hospital, paris, France, 3chru lille hospital, lille, France, 4Service de Médecine interne, Hôpital Louis-Mourier, colombes, France, 5Department of Internal Medicine, AP-HP Bichat Hospital, Paris, France, 6Internal Medicine, Hôpital Bichat, Université Paris-Diderot, Paris, France, 7Paris University, Internal medicine, Paris, France, 8foch hospital, foch, France, 9Internal Medicine, Valence Hospital, Valence, France, 10service de médecine interne, CH Poitiers, CHU Poitiers, poitiers, France, 11CHU de Nîmes, nimes, France, 12Internal Medicine, Hospital Avicenne, Bobigny, France, 13Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, 14Internal Medicine Department, Limoges, France, 15CH René Dubos, Pontoise, France, 16valenciennes hospital, valenciennes, France, 17INTERNAL MEDICINE, tours, France, 18Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 19CHU Angers, department of Internal Medicine, Angers, France, 20rennes CHU hospital, rennes, France, 21Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, 22Centre hospitalier niort, niort, France, 23Service de médecine interne. Hôpital Saint-Antoine., Paris, France, 24DHU2iB, Internal Medicine Saint Antoine Hospital, PARIS, France

    Background/Purpose: Methods:   Sixty two patients were included with median age 37 [2-76] and 31/62 (50%) women. At the diagnosis, 61 (98%) had audiovestibular involvement,…
  • Abstract Number: 907 • 2016 ACR/ARHP Annual Meeting

    Rituximab in Patients with Takayasu Arteritis: A Single Center Experience on Five Patients

    Giulia Pazzola1, Francesco Muratore1, Luigi Boiardi2, Mariagazia Catanoso1, Alessandra Soriano3, Pierluigi Macchioni1, Lucia Spaggiari4, Massimiliano Casali5, Nicolò Pipitone1, Niccolò Possemato6 and Carlo Salvarani1, 1Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 2Rheumatology Unit, Arcispedale S.Maria Nuova, IRCCS, Reggio Emilia, Italy, 3Rheumatology Unti, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 4Radiology, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 5Nuclear Medicine, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 6Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy

    Background/Purpose: Takayasu arteritis (TAK) is a large vessel vasculitis involving the aorta and its major branches in patients younger than 40 years. Glucocorticoids (GCs) are…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology